James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, and Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), recently participated in a U.S. Senate National Institutes of Health (NIH) caucus briefing held in Washington, D.C., by Senate NIH caucus co-chairs Sens. Lindsey Graham (R-SC) and Dick Durbin (D-IL).

Two survivors of a 2014 Ebola outbreak in Nigeria visited Vanderbilt University Medical Center last week to share their experiences and participate in a study aimed at finding ways to treat the often-fatal infection.

Three Nigerian physicians who survived Ebola virus disease in July 2014 after coming in direct contact with an Ebola-infected patient will speak at Vanderbilt University Medical Center next Wednesday, Sept. 16.

Vanderbilt University researchers next month will launch a major initiative to acquire “dense genotypes” from 100,000 individuals whose medical histories are known.

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.

In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States.

With the help of a computer program called “Rosetta,” researchers at Vanderbilt University have “redesigned” an antibody that has increased potency and can neutralize more strains of the AIDS-causing human immunodeficiency virus (HIV) than can any known natural antibody.